Nós temos câncer renal - Kidney Cancer Association
Nós temos câncer renal - Kidney Cancer Association
Nós temos câncer renal - Kidney Cancer Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Capítulo 3: Tratamento cirúrgico<br />
13. Flanigan RC, Blumenstein BA, Salmon S, et al. Cytoreduction nephrectomy in metastatic <strong>renal</strong><br />
cancer: the results of southwest oncology group trial 8949 (resumo). J Urol. 2000; 163:154. Resumo<br />
685.<br />
14. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized <strong>renal</strong> cell<br />
carcinoma: 10-year followup.J Urol. 2000; 163:442-445.<br />
15. Gill IS, Schweizer D, Hobart MG, Sung GT, Klein EA, Novick AC. Retroperitoneal laparoscopic radical<br />
nephrectomy: the Cleveland Clinic experience. J Urol. 2000; 163:1665-1670.<br />
16. Wolf JS JR, Seifman BD, Montie JE. Nephron sparing surgery for suspected malignancy: open surgery<br />
compared to laparoscopy with selective use of hand assistance. J Urol. 2000; 163: 1659-1664.<br />
17. Rodriguez R, Chan DY, Bishoff JT, et al. Renal ablative cryosurgery in selected patients with<br />
peripheral <strong>renal</strong> masses. Urology. 2000; 55:25-30.<br />
18. Wolf JS JR, Seifman BD, Montie JE. Nephron sparing surgery for suspected malignancy: open surgery<br />
compared to laparoscopy with selective use of hand assistance. J Urol. 2000; 163: 1659-1664.<br />
Capítulo 4: Terapias para <strong>câncer</strong> <strong>renal</strong> avançado<br />
19. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor<br />
sorefenib (BAY 43-9006) in patients with advanced <strong>renal</strong> cell carcinoma (RCC). J Clin Oncol 23: 1093s,<br />
2005 (supl.; resumo 4510)<br />
20. Motzer RJ, Michaelson MD, Racman, BG, et al: Activity of SU11246, a multitargeted inhibitor of<br />
vascular endothelial growth factor receptor and platelet-derived growth factor receptor in patients with<br />
metastatic <strong>renal</strong> cell carcinoma. J Clin Oncol 24:16-24, 2006. Motzer RJ, Rini BI, Bukowski, RM, et al:<br />
Sunitinib in patients with metastatic <strong>renal</strong> cell carcinoma. JAMA 295-2516-2524, 2006.<br />
21. Averous JJ, Proud CCG. When translation meets transformation; the mTOR story. Oncogene. 2006;<br />
25(48):6423-6435.<br />
22. Easton JJB, Houghton PPJ. mTOR and cancer therapy. Oncogene. 2006; 25(48):6436-6446.<br />
23. Wullschleger S, LoewithR, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124 (3); 471-<br />
484.<br />
24. Bjornsti and Houghton. Nat Rev <strong>Cancer</strong>, 2004; 4:335-348.<br />
25. Crespo and Hall. Microbiol Mol Biol Rev, 2002; 66:579-591.
Change language